Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes

Nayyar Iqbal,1 Elsie Allen,1 Peter Öhman2 1Bristol-Myers Squibb, Princeton, NJ, USA; 2AstraZeneca, Wilmington, DE, USA Background: Treatment decisions for older patients with type 2 diabetes mellitus must balance glycemic control and adverse event risk. The objective of this study was to...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Iqbal N, Allen E, Öhman P
Format: article
Langue:EN
Publié: Dove Medical Press 2014
Sujets:
Accès en ligne:https://doaj.org/article/915c0e3d89df41358c1cd94b691a1646
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!